Table 4 Univariable analysis of predictors for DSS in patients with metastatic ASPS
From: Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study
Variable | N | % | 5-year DSS | p value |
|---|---|---|---|---|
Age (median: years) | Â | Â | Â | 0.911 |
  ≤ 25 years | 30 | 35% | 64% |  |
  > 25 years | 56 | 65% | 60% |  |
Sex | Â | Â | Â | 0.997 |
 Male | 33 | 38% | 63% |  |
 Female | 53 | 62% | 61% |  |
Tumor site | Â | Â | Â | 0.542 |
 Lower extremity | 55 | 64% | 68% |  |
 Upper extremity | 6 | 7% | 75% |  |
 Trunk | 24 | 28% | 55% |  |
 Head and neck | 1 | 1% | 0% |  |
Tumor depth | Â | Â | Â | 0.006 |
 Superficial | 1 | 1% | 0% |  |
 Deep | 85 | 99% | 63% |  |
Tumor size | Â | Â | Â | 0.719 |
  ≤ 5 cm | 11 | 13% | 83% |  |
  > 5 cm, ≤ 10 cm | 54 | 63% | 54% |  |
  > 10 cm | 21 | 24% | 76% |  |
Resection of the primary site | Â | Â | Â | 0.559 |
 No | 29 | 34% | 51% |  |
 Yes | 57 | 66% | 68% |  |
Resection of the metastatic site | Â | Â | Â | 0.143 |
 No | 75 | 87% | 62% |  |
 Yes | 11 | 13% | 67% |  |
RT | Â | Â | Â | 0.614 |
 No | 73 | 85% | 61% |  |
 For primary lesion | 4 | 5% | 38% |  |
 For metastases | 9 | 11% | 73% |  |
Systemic treatment | Â | Â | Â | 0.470 |
 No | 38 | 44% | 73% |  |
 Conventional cytotoxic chemotherapy | 14 | 16% | 34% |  |
 Targeted therapy | 19 | 22% | 66% |  |
 Conventional cytotoxic chemotherapy + targeted therapy | 11 | 13% | 55% |  |
 Unknown | 4 | 5% | NA |  |
Regimen (information available; n = 44) | ||||
 DOX-based regimen |  |  |  | 0.033 |
 Yes | 23 | 27% | 39% |  |
 No | 21 | 24% | 75% |  |
Use of pazopanib | Â | Â | Â | 0.045 |
 Yes | 27 | 31% | 70% |  |
 No | 17 | 20% | 29% |  |